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Abstract
Context: A wide range (15–56%) of prevalences of anterior pituitary insufficiency are reported in
patients after traumatic brain injury (TBI). However, different study populations, study designs, and
diagnostic procedures were used. No data are available on emergency-department-based cohorts of
TBI patients.
Objective: To assess the prevalence of pituitary dysfunction in an emergency-department-based cohort
of TBI patients using strict endocrinological diagnostic criteria.
Methods: Of all the patients presenting in the emergency department with TBI over a 2-year period,
516 matched the inclusion criteria. One hundred and seven patients (77 with mild TBI and 30 with
moderate/severe TBI) agreed to participate. They were screened for anterior pituitary insufficiency by
GHRH–arginine testing, evaluation of fasting morning hormone levels (cortisol, TSH, free thyroxine,
FSH, LH, and 17b-estradiol or testosterone), and menstrual history 3–30 months after TBI. Abnormal
screening results were defined as low peak GH to GHRH–arginine, or low levels of any of the end-organ
hormones with low or normal pituitary hormone levels. Patients with abnormal screening results were
extensively evaluated, including additional hormone provocation tests (insulin tolerance test, ACTH
stimulation test, and repeated GHRH–arginine test) and assessment of free testosterone levels.
Results: Screening results were abnormal in 15 of 107 patients. In a subsequent extensive endocrine
evaluation, anterior pituitary dysfunction was diagnosed in only one patient (partial hypocortisolism).
Conclusion: By applying strict diagnostic criteria to an emergency-department-based cohort of TBI
patients, it was shown that anterior pituitary dysfunction is rare (!1%). Routine pituitary screening
in unselected patients after TBI is unlikely to be cost-effective.
European Journal of Endocrinology 162 19–28
Introduction
In Europe, the yearly incidence of traumatic brain
injury (TBI) is 100–300 per 100 000 persons (1, 2).
Head trauma can cause damage to any region in the
brain (3). Involvement of the posterior pituitary gland
during the acute phase after severe head trauma has
been acknowledged for years, but trauma-induced
anterior pituitary dysfunction was considered rare (4).
However, several recent studies have reported of a high
frequency of anterior pituitary hormone insufficiency
between 2 weeks and 1.5 years after TBI, varying from
15 to 56% of patients with moderate or severe TBI
(Mod/STBI) (5–14).
Anterior pituitary hormone deficiencies are associ-
ated with cognitive impairment, depression, anxiety,
fatigue, apathy, and impaired quality of life (15–17),
problems that are also frequently reported by TBI
patients (18). Therefore, abnormal anterior pituitary
hormone levels after TBI might contribute to the
problems reported by TBI patients. Additionally, hypo-
gonadism may limit fertility, and hypocortisolism and
hypothyroidism can be disabling and life-threatening
(19, 20). Consequently, it was proposed that pituitary
function should be screened in all patients after Mod
or STBI, even in the absence of symptoms of hypo-
pituitarism (8, 21, 22).
It remains unknown whether the wide range of
reported frequencies of abnormal hormone levels
reflects true differences in the prevalence of pituitary
dysfunction – attributable to regional differences in
severity and treatment of trauma – or reflects differences
in patient selection and diagnostic criteria applied to
define pituitary dysfunction in the various studies.
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The objective of the present study was to assess the
prevalence of anterior pituitary function in an
emergency-department-based cohort of TBI patients
using strict endocrinological criteria. Contrary to
previous studies, all consecutive patients who had
presented at the emergency department (ED) with TBI
were eligible.
Subjects and methods
Since 1998, all TBI patients presenting at the ED of the
Radboud University Nijmegen Medical Centre (RUNMC,
a level I Dutch trauma center) are included in the
Radboud University Nijmegen Brain Injury Cohort
Study (RUBICS) if a neurologist and/or neurosurgeon
is consulted. According to our hospital protocol, a
neurologist and/or neurosurgeon is consulted at the ED
in case a head trauma patient presents with i) a
Glasgow Coma Scale (GCS) of 3–14, or ii) a GCS of 15
with loss of consciousness (LOC) and/or posttraumatic
amnesia (PTA), or iii) a GCS of 15 without LOC and PTA,
but fulfilling additional criteria: unclear or ambiguous
accident history, persisting or progressive headache,
nausea and vomiting, intoxication with alcohol or
drugs, epileptic seizures, coagulation disorders, platelet
aggregation inhibitors or oral anticoagulation use,
confusion, disorientation, feeling dazed, retrograde
amnesia, focal neurological deficits, age O60 or !2
years, high-energy accident, or visible trauma above the
clavicles (including signs of skull (base) fracture) (23).
According to the hospital admission GCS, TBI patients
are classified as mild (GCS 13–15), moderate (Mod)
(GCS 9–12), or severe (GCS %8) (23, 24). In RUBICS,
we register various clinical variables obtained from the
ambulance or helicopter trauma physician, the ED, the
intensive care unit (ICU), and the neurological and
neurosurgical ward. Six and twelve months after TBI,
the patients’ functional status is assessed by neurological
examination and Extended Glasgow Outcome Score
version (25). For the present study, injury characteristics
were derived from the RUBICS database. Additionally,
we assessed actual body weight and length.
The ethics committee of the RUNMC approved the
present study protocol. All patients gave informed
consent before study entry.
Selection of patients
We reviewed RUBICS data of all the consecutive patients
(nZ1425) presenting within 24 h after TBI at the ED
between November 2004 and November 2006.
Inclusion criteria were age between 18 and 65 years,
and speaking Dutch. Exclusion criteria were known
neuroendocrine disorders, previous evaluation in the
pre-TBI period for neuroendocrine disturbances, gluco-
corticoid therapy within 3 months before study
entry, current alcohol or drug abuse limiting daily
functioning, other diseases substantially reducing life
expectancy, inability to agree to participate (including
mental retardation and dementia), obesity (body mass
index (BMI) O30 kg/m2), pregnancy, and lactation.
All 516 eligible patients (451 with a mild TBI (MTBI)
and 65 with Mod to severe TBI (STBI); Fig. 1) received
an invitation for hormonal evaluation. If pituitary
dysfunction is a consequence of TBI, it seems reasonable
to assume that the risk of pituitary dysfunction is higher
in patients with more severe TBI. Therefore, in case of
no response to the invitation within 4 weeks, we
additionally contacted all patients with Mod/STBI and a
random set of patients with MTBI by phone. Ultimately,
of the 516 eligible patients, 107 agreed to participate
(77 with MTBI and 30 with Mod/STBI), and they were
evaluated for pituitary dysfunction.
Study design
During the first visit, all patients were screened for
insufficient function of the anterior pituitary gland. All
patients with abnormal screening results were referred
to the endocrinology department for extensive evalu-
ation. The primary endpoint was pituitary dysfunction,
which was confirmed by extensive endocrine
evaluation.
Screening for insufficient pituitary function
All patients were screened by a GHRH–arginine
provocation test (100 mg GHRH i.v. bolus injection,
immediately followed by infusion of an arginine solution
(30 g in 30 min)). Baseline (0900 h in fasting state,
30 min after insertion of an i.v. catheter) serum levels
of cortisol, TSH, free thyroxine (fT4), FSH, LH, and
17b-estradiol (E2) (females) or testosterone (males) were
assessed. Additionally, premenopausal females were
interviewed regarding their menstrual pattern.
Abnormal screening results were defined as 1) peak
GH level below 3.5 mg/l (GHRH–arginine test) (26); 2)
level of any of the fasting 0900 h end-organ hormones
below the reference range of our laboratory (i.e.
cortisol!0.20 mmol/l, fT4!8 pmol/l, total testosterone
!11 nmol/l in males, E2!10 pmol/l in premenopausal
females – not using oral contraceptives – in the follicular
phase, and E2 !220 pmol/l in the luteal phase) with
low or normal pituitary hormone levels (i.e. TSH
!4.0 mU/l; LH !8.5 U/l and FSH !11 U/l in males;
LH !16 U/l and FSH !19 U/l in the follicular phase;
LH !19 U/l and FSH !15 U/l in the luteal phase).
Low gonadotropin levels in postmenopausal women were
defined as LH !12 U/l and FSH !37 U/l. Premeno-
pausal females who met the biochemical criteria of
hypogonadism were classified as having an abnormal
gonadal screening result if they were amenorrheic for
more than 6 months.
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Extensive evaluation after abnormal screening
for insufficient pituitary function
Patients with one or more abnormal screening results
were further evaluated by an endocrinologist within
2 months of the initial screening. Patients with
abnormal somatotropic or corticotropic screening
results underwent an insulin tolerance test (ITT; with
lowest glucose level !2.0 mmol/l). In case of contra-
indication to ITT, in patients with abnormal somato-
tropic screening results, the GHRH–arginine test was
repeated, whereas in patients with abnormal cortico-
tropic screening results an ACTH stimulation test using
250 mg synthetic ACTH(1–24) was performed. In males
with abnormal gonadal screening results, serum-free
testosterone was both directly measured and calculated
(27). In males with one or both measures of free
testosterone below 120 pmol/l (28), the evaluation
of total and free testosterone levels was repeated.
In patients with abnormal thyrotropic screening results,
the evaluation of TSH and fT4 levels was repeated.
Definitive pituitary dysfunction was diagnosed if one of
the pituitary axes was disturbed at the extensive
endocrinological evaluation. GHD was diagnosed in
case of low peak GH to both GHRH–arginine test and ITT
(i.e. maximum GH response !3.5 mg/l to GHRH–
arginine test and maximum GH response !3.4 mg/l
during ITT (26)), or during two GHRH–arginine tests.
Hypocortisolism was defined as a low basal cortisol level
with a low cortisol response during ITT (i.e. maximum
cortisol response!0.55 mmol/l) or synthetic ACTH(1–24)
(i.e. maximum cortisol response!0.58 mmol/l). Central
hypothyroidism was defined as low fT4 with low or
normal TSH at two consecutive occasions. Hypogonad-
ism was defined as low total and free testosterone with
low or normal FSH and LH at two consecutive occasions
(males); persistent amenorrhea with low E2 and low or
Figure 1 Patient selection flowchart.
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normal FSH and LH at two consecutive occasions
(premenopausal females); or low LH and FSH at two
consecutive occasions (postmenopausal females).
Analytical procedures
Serum GH was measured by RIA using an antiserum
against recombinant human GH, which was raised in a
guinea pig. The same preparation was used for radio-
iodination. The second (98/754) international standard
for GH was used for the standard curve. Separation of
bound and free hormone was performed by a second
antibody technique. The detection limit was 0.536 mg/l.
Within and between coefficient of variations (CV) were
7.1 and 10.5%, 4.3 and 8.2%, 5.4 and 10.9% at levels
2.01, 3.62, and 11.79 mg/l respectively. Serum TSH was
measured by immunoluminometric assay (ILMA)
incorporated in a random access analyzer (Architect,
Abbott Diagnostics). Serum fT4 was estimated by a
luminescence enzyme immunoassay incorporated in a
random access assay system (Vitros ECI, Ortho Clinical
Diagnostics, Beerse, Belgium).
Serum testosterone was assessed by 3H-RIA after
ether extraction of the samples, including correction for
procedural losses (29). Symmetric dialysis for the
measurement of the free testosterone fraction (free/total
ratio) was performed as described previously (29) with
the following modifications: samples were diluted 1C1
Table 1 Characteristics of the eligible patients before study entry. Data are separately presented for participants, and for patients meeting
the selection criteria of this study but not participating in the endocrine evaluation (nonparticipants).
Participants Nonparticipants
Variable MTBI (nZ77)† Mod/STBI (nZ30)† MTBI (nZ374) Mod/STBI (nZ35)
Pre-injury
Age (years) 45 (22–63)* 36 (21–62) 35 (21–61) 36 (20–65)
Male gender 50 (65%) 20 (67%) 260 (70%) 28 (80%)
Physical comorbidity 52 (68%)* 17 (57%) 189 (51%) 14 (40%)
Prior head injury 4 (5%) 0 (0%) 15 (4%) 1 (3%)
Peri-injury
Admission GCS 15 (3–15) 3 (3–12) 15 (13–15) 3 (3–12)
Mechanism of injury
Traffic 34 (44%) 19 (63%) 183 (49%) 23 (66%)
Fall 23 (30%) 6 (20%) 91 (24%) 10 (29%)
Sports 9 (12%) 3 (10%) 36 (10%) 1 (3%)
Other 11 (14%) 2 (7%) 65 (17%) 1 (3%)
Hypoxia at entry in ED 5 (6%) 7 (23%) 10 (3%) 5 (14%)
Hypotension at entry in ED 5 (6%)* 7 (23%) 4 (1%) 5 (14%)
Loss of consciousness 44 (57%) 29 (97%) 188 (50%) 33 (94%)
Duration of PTA
No PTA 38 (49%) 1 (3%) 175 (47%) 0 (0%)
PTA 1–30 min 30 (39%) 0 (0%) 142 (38%) 0 (0%)
PTAO30 min 9 (12%) 29 (97%) 57 (15%) 35 (100%)
Headache on admission 23 (31%) 1 (14%) 106 (29%) 0 (0%)
Headache not applicablea 2 23 3 23
Nausea or vomiting 10 (13%) 0 (0%) 63 (17%) 0 (0%)
CT characteristics
No CT made 19 (25%) 0 (0%) 77 (21%) 0 (0%)
No traumatic abnormalities 41 (53%) 1 (3%) 233 (62%) 4 (11%)
Traumatic abnormalities 17 (22%) 29 (97%) 64 (17%) 31 (89%)
Additional extracranial injuries 59 (77%)† 25 (83%) 181 (48%) 25 (71%)
ISS 9 (2–41) 35 (10–62)* 6 (2–29) 20 (9–50)
Hospitalization 42 (55%) 30 (100%) 214 (57%) 35 (100%)
ICU 11 (14%) 27 (90%) 22 (6%) 29 (83%)
Other ward 31 (40%) 3 (10%) 192 (51%) 6 (17%)
Cranial surgery performed 1 (1%) 3 (10%) 5 (1%) 1 (3%)
Post-injury
Interval between TBI and endocrine
evaluation (months)
13 (5–29)* 14 (5–28) 18 (7–29) 19 (6–32)
GOS-E 3–9 months after TBI 7 (4–8) 6 (3–8) 7 (5–8) 6 (3–8)
GOS-E 9–15 months after TBI 8 (5–8) 7 (3–8) 8 (6–8) 6 (3–8)
BMI (kg/m2) 25 (19–30) 24 (21–29) – –
Data are shown as number (percentage) or as median (5–95th percentile). BMI, body mass index; GCS, Glasgow Coma Scale score; GOS-E, Extended
Glasgow Outcome Scale Score version (range 1–8, higher score refers to a better functional outcome); ICU, intensive care unit; ISS, injury severity scale score
(range 0–75, lower score refers to lower severity of injury to various body regions) (22); MTBI, mild traumatic brain injury; Mod/STBI, moderate to severe
traumatic brain injury; n, number of patients; PTA, posttraumatic amnesia. *P!0.01 for the difference between participants and nonparticipants with a similar
severity of TBI; †P!0.001.
aHeadache on admission only applicable for patients without loss of consciousness or with loss of consciousness for!30 min.
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with HEPES buffer prior to dialysis. Aliquots, 180 ml,
were taken to pipette on both sides of the membrane,
and the dialysis time was 2.5 h. As a calibrator, we used
pooled serum that had been spiked with 100 nmol/l
testosterone, in which the free testosterone fraction had
been assessed by equilibrium dialysis with total
testosterone assessment. The within-assay CV was
5.4% (nZ45), and the between-assay CV (of duplicate
means) were 4.6 and 6.4% at mean percent free
testosterone levels 1.12 and 1.01% respectively
(nZ6). We calculated a free testosterone index from
total testosterone and sex hormone binding globulin
(SHBG) concentrations using estimates based on the
algorithm we recently developed to evaluate equilibrium
constants of testosterone and SHBG or albumin from
serum-free testosterone measurements by a near-reference
method, i.e. symmetric dialysis (27). This free testoster-
one index perfectly matches with the free testosterone
concentrations measured by symmetric dialysis. SHBG
was measured by a commercial ILMA performed on an
Abbott Architect Immunoanalyzer (Abbott).
E2 was evaluated after ether extraction of 0.5 ml serum
to which recovery tracer was added, followed by
chromatography on Sephadex LH20 columns by RIA (30).
Serum FSH and LH were determined with fluor-
escenceimmunoenzymaticassay (Abbott Diagnostics)
using a random access analyzer (Type AxSYM; Abbott).
Serum total cortisol was measured by luminescence
immunoassay on an Architect random access
analyzer (Abbott).
Statistical analyses
Data were analyzed using SPSS software version 12.0.
To evaluate whether the participants with MTBI were a
representative sample of all the eligible patients with
MTBI and whether the participants with Mod/STBI
were representative for all the patients with Mod/STBI,
participants, and nonparticipants (i.e. patients meeting
the study criteria but not participating in the hormonal
evaluations) were compared using the two-sample t-test
in case of continuous measures, Wilcoxon–Mann–
Whitney test for ordinal data, and c2 test for frequency
data. To correct for multiple testings, a P value!0.01
was considered significant. Prevalences of pituitary
dysfunction were described as percentages with exact
95% confidence intervals (CIs) of prevalences.
Results
Patient characteristics
Compared with nonparticipants with MTBI, partici-
pants with MTBI had more prognostically unfavorable
characteristics (i.e. a higher age, more comorbidity, and
more extracranial injury), and a shorter interval
between TBI and endocrine evaluation (median 13 vs
18 months). Participants with Mod/STBI had higher
injury severity scores (31) as compared with non-
participants with Mod/STBI. No relation was found
between the severity of TBI and interval between TBI
and endocrine evaluation (Table 1).
Endocrine evaluation
While screening the 107 patients for insufficient
pituitary function, 15 patients (14.0%) with abnormal
results were identified. The results of this initial
screening were abnormal for the following axes:
GH–insulin-like growth factor 1 (IGF1; nZ1), pitu-
itary–gonadal (nZ7 males), pituitary–adrenal (nZ6),
and pituitary–thyroid (nZ1) axes (Table 2).
In a subsequent extensive endocrine evaluation of
all the 15 patients with initial abnormal screening
results, 14 patients were found to have hormone levels
within the reference levels of our laboratory (Table 2).
Table 2 Results of extensive endocrine evaluation in patients with abnormal hormonal screening results.
Sex Age (years) Severity of TBI Screening results Results of extensive endocrine evaluation
F 31 MTBI TSH 1.28 mU/l; fT4
7.9 pmol/l
Follow-up thyroid: TSH 1.69 mU/l; fT4 8.4 pmol/l
F 53 MTBI Cort 0.15 mmol/l ITT: peak cort 0.50 mmol/l, peak ACTH 62.2 pmol/l
F 39 ModTBI Cort 0.14 mmol/l ITT: peak cort 0.65 mmol/l, peak ACTH 39.2 pmol/l
M 34 MTBI Cort 0.18 mmol/l ITT: peak cort 0.57 mmol/l, peak ACTH 41.2 pmol/l
M 46 MTBI Cort 0.19 mmol/l ITT: peak cort 0.59 mmol/l, peak ACTH 36.3 pmol/l
M 58 MTBI Cort 0.15 mmol/l ITT: peak cort 0.58 mmol/l, peak ACTH 63.0 pmol/l
M 55 MTBI Cort 0.15 mmol/l ITT: peak cort 0.57 mmol/l, peak ACTH 24.2 pmol/l
M 33 MTBI GHRH–arginine test:
peak GH 2.35 mg/l
ITT contraindicated (epileptic seizures)
GHRH–arginine test: peak GH 3.69 mg/l
M 36 MTBI Test 10.3 nmol/l fTestd 333 pmol/l; fTestc 294 pmol/l
M 59 MTBI Test 8.04 nmol/l fTestd 137 pmol/l; fTestc 155 pmol/l
M 22 MTBI Test 10.6 nmol/l fTestd 257 pmol/l; fTestc 288 pmol/l
M 41 MTBI Test 9.3 nmol/l fTestd 260 pmol/l; fTestc 231 pmol/l
M 44 STBI Test 7.79 nmol/l fTestd 223 pmol/l; fTestc 201 pmol/l
M 49 STBI Test 8.47 nmol/l fTestd 187 pmol/l; fTestc 202 pmol/l
M 41 STBI Test 10.3 nmol/l fTestd 139 pmol/l; fTestc 259 pmol/l
Cort, cortisol; F, female; fT4, free thyroxine; fTestc, calculated free testosterone; fTestd, determined free testosterone; GHD, GH deficiency; M, male; MTBI,
mild TBI; ModTBI, moderate TBI; STBI, severe TBI; TBI, traumatic brain injury; Test, total testosterone.
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Partial hypocortisolism was diagnosed in one MTBI
patient. Therefore, the prevalence of definitive pituitary
dysfunction in our ED-based cohort of TBI patients was
0.9% (95% CI 0.0–5.0%).
Discussion
In this study, !1% of the patients had pituitary
dysfunction between 3 and 30 months after presen-
tation at the ED with TBI. In all the 30 patients
with Mod/STBI participating in our study, anterior
pituitary function was normal. The prevalence of
hypopituitarism after TBI that we report is considerably
lower than the prevalences reported by recent studies
(15–56%) (5–14). The aim of our study was to evaluate
anterior pituitary function in a patient cohort repre-
sentative for all the patients with TBI. Therefore, it is not
surprising that our study showed a lower frequency of
hypopituitarism compared with previous studies. In
these previous studies (5, 7–14), the percentage of
patients with Mod/STBI was higher (56–100%) than
that of the patients in our study. In addition to the
differences in the study cohorts, the wide range of
reported prevalences of hypopituitarism (varying from
15 to 56%) may be attributed to the differences in
diagnostic criteria (5–14). Furthermore, some studies
included patients in whom, besides a history of TBI,
alternative causes of pituitary dysfunction had not been
ruled out, such as pre-existent hypopituitarism (6–10,
12, 14), BMI above 30 kg/m2 (5–10, 12–14), and
substance abuse (6–10, 12). These differences hinder
the comparison of the findings of previous reports with
our findings.
Table 3 summarizes the selection criteria and patient
characteristics of ten previous studies on post-TBI
hypopituitarism beyond the subacute phase, i.e. O5
months after TBI. Some authors did not unequivocally
specify the population from which the study population
was selected, or did not unequivocally define the
selection criteria (6, 10, 12, 13). Consequently, the
population in which the prevalence of pituitary
dysfunction was assessed remained insufficiently
defined. Contrary to our study, patients who were
evaluated in all previous studies were selected from
hospitalized patient populations only (at a general ward
(5, 7, 8, 10, 13, 14), at an ICU (9, 12), or at a
rehabilitation institute (11)). Therefore, these studies
included patients with more severe brain injury. In our
study, all patients presenting at our ED with TBI were
eligible, whether or not hospitalized thereafter. This
approach increased the probability that the sample of
TBI patients we evaluated was representative for a
general TBI population.
Some demographic and injury characteristics were
unfavorable in MTBI patients participating in our study
compared with MTBI patients who did not participate.
In some previous studies, no association of pituitary
dysfunction with TBI severity was reported (6, 7,
10–13), whereas others found pituitary dysfunction to
be more prevalent in patients with more severe TBI (5,
14). In their systematic review, Schneider et al. pooled
the reported prevalences in severe (35.3%, 95% CI
27.3–44.2%), Mod (10.9%, 95% CI 5.1–21.8%), and
MTBI (16.8%, 95% CI 10.9–25.0%) (22), showing that
the risk of pituitary dysfunction is higher in patients
with STBI than in patients with a MTBI. In order to
prevent the underestimation of the prevalence of
pituitary dysfunction, our study enrolment procedure
implied that the largest effort was made to include
patients with Mod/STBI, resulting in an overrepresenta-
tion of Mod/STBI patients. Therefore, the low preva-
lence of anterior pituitary dysfunction in our study
cohort is unlikely to be an underestimation of the true
prevalence of TBI-induced pituitary dysfunction.
Our results show that a strict differentiation should be
made between definitive ‘pituitary dysfunction’ and
‘abnormal results of hormonal screening’. Indeed, in
our study, results of hormonal screening were fre-
quently abnormal (14% of the patients), whereas
definitive pituitary dysfunction was rare (!1% of the
patients). Supplementary Table 1 (see section on
supplementary data given at the end of this article)
summarizes diagnostic criteria applied in ten previous
studies and the reported prevalences of pituitary
dysfunction.
We and four other groups used the GHRH–
arginine test as the primary test to evaluate the
GH–IGF1 axis (5, 6, 11, 13). Only one of those groups
required confirmation by a second test, the ITT, like
we did (13). For the GHRH–arginine test, previous
authors used a peak GH of 9.0 mg/l as a cut-off value
(5, 6, 11, 13), whereas recent clinical practice
guidelines recommend 4.1 mg/l (26). Of our 107
patients, 13 patients (12%) had a peak GH response
below 9.0 mg/l. This observation is in line with the
results of previous studies defining GHD based on
GHRH–arginine testing and using 9.0 mg/l as a cut-off
value (median 9.5%, range 8–23%) (5, 6, 11, 13).
Bondanelli et al. defined even patients with peak GH
!16.5 mg/l as hypopituitaristic. Indeed, they reported
a very high prevalence of hypopituitarism (i.e. 54%)
(5). Such patients are unlikely to benefit from hormone
substitution, and most health assurance companies
will not reimburse GH substitution in these cases.
Comparison of absolute hormone levels between the
studies is intricate, as even after harmonization the
performance of various immunoassays varies widely.
For example, after harmonization, the interlaboratory
CV of GH measurements is at least 7% (32).
The diagnosis of secondary hypogonadism is challen-
ging as no consensus exists. Most preceding studies
define hypogonadism as low or normal LH and
FSH levels with a low total testosterone level (5–8, 10,
11, 13), or less frequently a low free testosterone level
(9, 12, 14). Klose et al. were the only authors requiring
26 AW van der Eerden and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010) 162
www.eje-online.org
confirmation of low testosterone levels in a second
visit (14). Seven percent of our male patients had
onetime low total testosterone with low or normal LH
and FSH. Leal-Cerro et al. used a GnRH provocation test,
but they did not specify how patients were selected for
GnRH testing (9). Two previous studies defined
secondary hypogonadism in females as low levels of
E2, LH, and FSH (5, 12). Most studies, however, included
additional criteria, such as the presence of menstrual
disturbances (6, 9, 10, 14) or secondary amenorrhea
(7, 8, 11, 13), like we did. None of our female patients
was amenorrheic with low E2 and low or normal LH
and FSH.
Aimaretti et al. defined hypocortisolism as onetime
low serum cortisol or a decreased level of 24-h urinary
free cortisol (6). Six percent of our patients had a low
serum cortisol level at screening, but hypocortisolism
was confirmed in only one patient. The prevalence of
low basal serum cortisol levels in our TBI population is
similar to the prevalence in an unselected sample from
the general Dutch population (33). Some authors did
not specify their criteria for hypocortisolism (5, 10).
However, most authors diagnosed hypocortisolism with
a hormone provocation test (such as ITT (7, 9, 13, 14),
glucagon stimulation test (7, 8), or short ACTH
stimulation test (7, 11, 14)). Groups basing their
definition of hypocortisolism on basal cortisol levels,
glucagon stimulation test, or ACTH stimulation test
found a relatively high prevalence of hypocortisolism
(range 5–19%) (6–8, 11, 12). Like we did, four other
groups used an ITT (7, 9, 13, 14), two of which specified
the selection criteria for patients to undergo ITT (7, 14).
Three of them found a low prevalence of hypocortiso-
lism: 1–6% (9, 13, 14), whereas Agha et al. found 13%
(7). Klose et al. found that 3.3% of their age- and
BMI-matched controls had a cortisol response meeting
their definition of hypocortisolism (14).
Hypothyroidism was mostly assessed by low fT4 and
low or normal TSH according to local reference ranges
(5, 6, 12, 13), or without a specification of local
reference ranges (7, 8, 11). One percent of our patients
had onetime low fT4 with low or normal TSH. Klose
et al. were the only authors requiring persistence of
low fT4, like we did (14). Leal-Cerro et al. additionally
used a TRH stimulation test (in some, but not in
all patients) (9).
A limitation of this study is that because of the very
low frequency of hypopituitarism, no risk factors for
pituitary dysfunction could be identified. Another
limitation is the use of a stimulation test of the
pituitary–adrenal axis only in patients who had low
basal cortisol levels. This strategy cannot unequivocally
exclude relative pituitary–adrenal dysfunction.
However, a low basal cortisol level does exclude absolute
pituitary–adrenal dysfunction.
In conclusion, our findings show that the results of
hormonal screening are abnormal in a significant
proportion of patients who originally presented at the
ED with TBI, but that definite pituitary dysfunction is
rare. Therefore, routine screening for hormone disturb-
ances in unselected patients after TBI is unlikely to be
cost-effective. However, screening should be advised in
all patients with symptoms and signs of hypopituitarism
and a history of TBI, and based on earlier reports,
probably also in patients with more severe forms of TBI
(e.g. those necessitating neurosurgical intervention or
admission to an ICU).
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/
10.1530/EJE-09-0436.
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